Skip to content

US · NVO · DRUG MANUFACTURERS - GENERAL

Novo Nordisk A/S (NVO) intrinsic value and stock valuation

$37.82as of 2026-11-21 · Mkt cap 197.66B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Novo Nordisk A/S DCF and intrinsic value

InvestorsCraft values NVO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NVO’s statements →

Novo Nordisk A/S Graham Number

Graham Number: $150.35d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Bagsvaerd, CR 2880 novonordisk.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$309.1B+19.5% 5y CAGRd
20112025
Net income
$102.4B+19.4% 5y CAGRd
20112025
Free cash flow
$29B-0.6% 5y CAGRd
20112025
Total equity
$194B+79.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$309.1B$290.4B$232.3B$177B$140.8B
Operating income$127.7B$128.3B$102.6B$74.8B$58.6B
Net income$102.4B$101B$83.7B$55.5B$47.8B
EPSd$23M$22.6M$18.6M$12.2M$10.4M
Operating cash flow$119.1B$121B$108.9B$78.9B$55B
Capital expenditure-$-90.11B-$-51.31B-$-38.9B-$-14.75B-$-7.39B
Free cash flow$29B$69.7B$70B$64.1B$47.6B
Total assets$542.9B$465.8B$314.5B$241.3B$194.5B
Total debt$131B$102.8B$27B$25.8B$26.6B
Net debt$104.5B$87.1B$12.6B$13.1B$15.9B
Total equity$194B$143.5B$106.6B$83.5B$70.7B
Cash and short-term investments$27B$26.3B$30.2B$23.6B$17.5B
Income statement
20252024202320222021
Revenue$309.1B$290.4B$232.3B$177B$140.8B
Cost of revenue$58.8B$44.5B$35.8B$28.4B$23.7B
Gross profit$250.3B$245.9B$196.5B$148.5B$117.1B
Research and development expenses$52B$48.1B$32.4B$24B$17.8B
Selling, general and administrative expenses$70.3B$67.4B$61.6B$50.7B$41.1B
Other expenses$300M$2.1B-$-119M-$-1.03B-$-332M
Operating expenses$122.6B$117.5B$93.9B$73.7B$58.5B
Cost and expenses$181.4B$162.1B$129.7B$102.1B$82.2B
Interest income$1.27B$1.84B$1.07B$239M$231M
Interest expense$4.21B$1.64B$542M$378M$289M
Depreciation and amortization$22B$19.1B$9.41B$7.36B$6.03B
Ebitda$156.7B$147.9B$114.6B$76.8B$65.4B
Operating income$127.7B$128.3B$102.6B$74.8B$58.6B
Total other income/expenses, net$2.88B-$-1.15B$2.1B-$-5.75B$436M
Income before tax$130.5B$127.2B$104.7B$69.1B$59.1B
Income tax expense$28.1B$26.2B$21B$13.5B$11.3B
Net income$102.4B$101B$83.7B$55.5B$47.8B
Weighted average shares outstanding$4.45B$4.45B$4.48B$4.53B$4.59B
Weighted average diluted shares outstanding$4.45B$4.46B$4.49B$4.54B$4.61B
Balance sheet
20252024202320222021
Cash and short-term investments$27B$26.3B$30.2B$23.6B$17.5B
Net receivables$75.7B$87.4B$75.3B$57.5B$46.8B
Inventory$49.6B$40.8B$31.8B$24.4B$19.6B
Total current assets$172.5B$160.9B$139.6B$108.2B$85.6B
Property, plant and equipment, net$208.4B$162.5B$91B$66.7B$55.4B
Goodwill and intangible assets$130.1B$111.1B$60.4B$51.4B$43.2B
Long-term investments$2.51B$2.68B$1.66B$1.34B$1.44B
Total non-current assets$370.4B$304.9B$174.8B$133.1B$108.9B
Total assets$542.9B$465.8B$314.5B$241.3B$194.5B
Accounts payable$19.8B$28.8B$25.6B$15.6B$8.87B
Short-term debt$12B$13.1B$6.48B$1.47B$13.7B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$215.7B$217.5B$169.7B$120.9B$99.5B
Long-term debt$118.9B$89.7B$20.5B$24.3B$13B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$133.2B$104.8B$38.3B$36.8B$24.2B
Capital lease obligations$8.57B$6.77B$5.73B$4.53B$4.13B
Total liabilities$348.9B$322.3B$207.9B$157.8B$123.8B
Common stock$446M$446M$451M$456M$462M
Retained earnings$195.3B$144.4B$104.8B$80.6B$72B
Accumulated other comprehensive income (loss)-$-1.7B-$-1.41B$1.28B$2.45B-$-1.71B
Total equity$194B$143.5B$106.6B$83.5B$70.7B
Total investments$3.01B$13.3B$17.5B$12.3B$8.21B
Total debt$131B$102.8B$27B$25.8B$26.6B
Net debt$104.5B$87.1B$12.6B$13.1B$15.9B
Cash flow statement
20252024202320222021
Net income$102.4B$101B$83.7B$55.5B$47.8B
Depreciation and amortization$22B$19.1B$9.41B$7.36B$6.03B
Stock-based compensation$0.00$2.29B$2.15B$1.54B$1.04B
Change in working capital$3.74B$2.59B-$-12.25B-$-5.54B-$-8.66B
Accounts receivable$0.00-$-14.31B-$-14.21B-$-10.82B-$-12.91B
Inventory$0.00-$-9.04B-$-7.42B-$-4.77B-$-1.09B
Accounts payable$0.00$3.24B$10B$6.72B$3.15B
Net cash provided by operating activities$119.1B$121B$108.9B$78.9B$55B
Investments in property, plant and equipment-$-60.14B-$-47.16B-$-25.81B-$-12.15B-$-7.39B
Acquisitions, net$1B-$-82.16B$0.00-$-7.08B-$-18.28B
Net cash used for investing activities-$-79.16B-$-128.9B-$-43.89B-$-24.92B-$-31.61B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-1.39B-$-20.18B-$-29.92B-$-24.09B-$-19.45B
Dividends paid-$-51.76B-$-44.14B-$-31.77B-$-25.3B-$-21.52B
Net cash used for financing activities-$-28.41B$8.74B-$-63.16B-$-51.8B-$-25.49B
Net change in cash$10.8B$1.26B$1.74B$1.93B-$-1.51B
Cash at end of period$26.5B$15.7B$14.4B$12.7B$10.7B
Operating cash flow$119.1B$121B$108.9B$78.9B$55B
Capital expenditure-$-90.11B-$-51.31B-$-38.9B-$-14.75B-$-7.39B
Free cash flow$29B$69.7B$70B$64.1B$47.6B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Novo Nordisk A/S

        Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

        CEO
        Maziar Mike Doustdar
        Employees
        68.79K
        Beta
        0.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Novo Nordisk A/S (NVO)?

        Novo Nordisk A/S (NVO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NVO undervalued?

        NVO trades at a price of $37.82 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.